期刊
JOURNAL OF HEPATOLOGY
卷 47, 期 1, 页码 37-45出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jhep.2007.02.010
关键词
liver; severe fibrosis; hepatitis C; cirrhosis; antiviral drugs; mortality; morbidity
Background/Aims: To examine the morbidity and mortality of patients with severe fibrosis secondary to HCV infection, within a population unbiased by tertiary referral. Methods: One hundred and fifty HCV infected patients were identified from the Trent HCV study with a liver biopsy taken before 2002 demonstrating severe fibrosis (Ishak stage >= 4). Follow-up data were extracted from the database and hospital records. Results: Median follow-up was 51 months. Of the 131 patients with no prior history of decompensation, 33 (25%) died (n = 25) or were transplanted (n = 8), after a median interval of 42 months. The probability of survival without liver transplantation was 97%, 88%, and 78% at 1, 3, and 5 years, respectively. Hepatocellular carcinoma and/or decompensation was diagnosed in 33 (25%), after a median interval of 41 months. In multivariate analysis, combination antiviral therapy was associated with improved survival. Prognosis was not affected by the Ishak stage at index biopsy. There was a worse prognosis for the 19 patients with previous decompensation; 17 (89%) having either died (n = 15) or been transplanted (n = 2). Conclusions: This study demonstrates that severe liver fibrosis (Ishak stage >= 4) secondary to hepatitis C is associated with a poor prognosis, that may be improved following combination antiviral treatment. (c) 2007 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据